BK1261 Pharmaceutical Outsourcing/contract Research Organization(cro Concept)
- 518.322
- +3.701+0.72%
Big Bank Ratings | Jefferies: From the perspective of market accounts, Yao Ming Biotech is currently at an inflection point rating “buying”
Big Bank Ratings | Jefferies: From the perspective of market accounts, Yao Ming Biotech is currently at an inflection point rating “buying”
Research and Development | China Merchants Securities: Drastic reduction in the target price of Pharmaceutical Biotech to HK$13, downgrading the rating to “neutral”
CICC cuts Mingkang's target price by 17.2% to HK$44.3, reflecting heightened geopolitical concerns
JOINN LABORATORIES(6127.HK):WAITING LONGER FOR RECOVERY TO MATERIALIZE
Nomura Adjusts Joinn Laboratories' Price Target to HK$10.41 From HK$12.60, Keeps at Neutral
UBS: Maintaining the “neutral” rating of Pharmacovigilance (02359), the target price was reduced to HK$40.1
Nomura Adjusts Pharmaron's Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy
Nomura Adjusts Asymchem Laboratories' Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy
Minsheng Securities released a research report on April 26 stating that Kanglong Chemical (300759.SZ) was given a recommended rating. The main reasons for the rating include: 1) laboratory services are recovering month-on-month, and new orders for small m
Nomura Adjusts Pharmaron Beijing Co's Price Target to HK$15.41 From HK$17.99, Keeps at Buy
Minsheng Securities released a research report on April 26 stating that it gave Gloria Ying (002821.SZ) a recommended rating. The main reasons for the rating include: 1) rapid revenue growth in the European and American markets, and continued deepening se
BOC International: Maintaining Kingsley Biotech's (01548) “Buy” Rating Target Price of HK$27.75
Kingsley Biotech (1548.HK): Approved for major indications, rapid release of CARVYKTI can be expected; focus on centralized implementation of 2H catalysts
Haitong International: Maintaining Fangda Holdings (01521)'s “superior to market” rating target price reduction of 44% to HK$1.89
Fangda Holdings (01521.HK): Short-term fluctuations in performance are optimistic about the company's long-term steady development
Guoxin Securities released a research report on April 15 stating that it gave Zhaoyan New Pharmaceutical (603127.SH) a purchase rating. The main reasons for the rating include: 1) revenue is basically flat throughout the year, and the profit side is under
Pharmaceutical Biotech (02269.HK): Opening a New Chapter in Global Operations, Multiple Engines Drive Growth
Capital Securities released a research report on April 12 stating that Kanglong Chemical (300759.SZ) was given a purchase rating. The main reasons for the rating include: 1) the decline in investment and financing sentiment affects business performance su
Bank Rating | Lyon: Upgraded Tiger Pharmaceuticals and Zhaoyan New Drug Ratings Benefit from Innovative Drug Support Policies